Orladeyo effective in HAE patients of different ages, data show
The use of Orladeyo (berotralstat) — widely approved as a preventive treatment for hereditary angioedema (HAE) — can help reduce the rates of swelling attacks in people with HAE of different ages, according to new data from clinical trials and real-world analyses. Biocryst Pharmaceuticals, the developer of the…